Axsome Therapeutics, Inc. AXSM shares are trading higher Wednesday following a recent corporate presentation.
What To Know: During the presentation, the company provided peak sales estimates for drugs in its portfolio.
Additionally, Mizuho analyst Graig Suvannavejh reiterated Axsome Therapeutics with a Buy and maintained the $95 price target.
Earlier this week, Morgan Stanley analyst Vikram Purohit maintained Axsome Therapeutics with a Equal-Weight and raised the price target from $87 to $90.
Related Link: Why Allogene Stock Is Trading Down Today
AXSM Price Action: Shares of AXSM were up 8.63% at $81.34 at the time of publication, according to Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
